Association between γ′ fibrinogen levels and inflammation

Kristine S. Alexander; Theresa E. Madden; David H. Farrell

doi:10.1160/TH10-09-0626

Thrombosis and Haemostasis, Inhaltsverzeichnis

Thromb Haemost 2011; 105(04): 605-609
DOI: 10.1160/TH10-09-0626

Blood Coagulation, Fibrinolysis and Cellular Haemostasis

Schattauer GmbH

Association between γ′ fibrinogen levels and inflammation

Kristine S. Alexander

¹Department of Molecular and Medical Genetics, School of Medicine, Oregon Health & Science University, Portland, Oregon, USA

,

Theresa E. Madden

²Dr. Theresa E. Madden & Associates, PLLC, Olympia, Washington, USA

,

David H. Farrell

³Division of Cardiovascular Medicine, Department of Medicine, School of Medicine, Oregon Health & Science University, Portland, Oregon, USA

› Institutsangaben

Abstract

Summary

The γ’ fibrinogen isoform produces clots that are stiffer and more resistant to breakdown than the more common fibrinogen isoform, γA. Increased levels of γ’ fibrinogen are associated with several forms of cardiovascular disease. The purpose of this cross-sectional study was to investigate the relationship between γ’ fibrinogen, an emerging risk factor for cardiovascular disease, and inflammatory markers in subjects with a chronic inflammatory state. The 284 subjects for this study came from the Periodontitis And Vascular Events (PAVE) study, and γ’ fibrinogen and total fibrinogen in plasma were measured by ELISA. Information on patient demographics and health status, as well as levels of C-reactive protein (CRP), an inflammatory marker, have previously been collected for this study. The mean (SE) γ’ fibrinogen level in the subjects was 0.622 (0.017) mg/ml. Levels of γ’ fibrinogen were correlated with CRP (p = 0.006), with a one unit increase in CRP associated with a 1.9% increase in γ’ fibrinogen, after adjustment for potential confounders. Total fibrinogen was not correlated with γ’ fibrinogen in these subjects. The number of dental sites with evidence of tissue inflammation was also significantly associated with γ’ fibrinogen levels. These results provide an important step in the evolution of γ’ fibrinogen not only as a general risk factor for cardiovascular disease, but as a potentially useful biomarker for assessing a patient’s inflammatory state and associated cardiovascular disease risk.

Keywords

Cardiovascular disease - γ’ fibrinogen - inflammation - periodontitis - risk factor

Volltext

Referenzen

References
1 Chung DW, Davie EW. γ and γ’ chains of human fibrinogen are produced by alternative mRNA processing. Biochemistry 1984; 23: 4232-4236.
2 Fornace Jr AJ, Cummings DE, Comeau CM. et al. Structure of the human γ-fibrinogen gene. Alternate mRNA splicing near the 3’ end of the gene produces γA and γB forms of γ-fibrinogen. J Biol Chem 1984; 259: 12826-12830.
3 Lovely RS, Falls LA, Al-Mondhiry HA. et al. Association of γA/γ’ fibrinogen levels and coronary artery disease. Thromb Haemost 2002; 88: 26-31.
4 Mannila MN, Lovely RS, Kazmierczak SC. et al. Elevated plasma fibrinogen γ’ concentration is associated with myocardial infarction: effects of variation in fibrinogen genes and environmental factors. J Thromb Haemost 2007; 5: 766-773.
5 Lovely RS, Kazmierczak SC, Massaro JM. et al. γ’ fibrinogen: evaluation of a new assay for study of associations with cardiovascular disease. Clin Chem 2010; 56: 781-788.
6 Meh DA, Siebenlist KR, Mosesson MW. Identification and characterization of the thrombin binding sites on fibrin. J Biol Chem 1996; 271: 23121-5.
7 Lovely RS, Moaddel M, Farrell DH. Fibrinogen γ’ chain binds thrombin exosite II. J Thromb Haemost 2003; 1: 124-131.
8 Pospisil CH, Stafford AR, Fredenburgh JC. et al. Evidence that both exosites on thrombin participate in its high affinity interaction with fibrin. J Biol Chem 2003; 278: 21584-21591.
9 Sabo TM, Farrell DH, Maurer MC. Conformational analysis of γ’ peptide (410–427) interactions with thrombin anion binding exosite II. Biochemistry 2006; 45: 7434-7445.
10 Pineda AO, Chen ZW, Marino F. et al. Crystal structure of thrombin in complex with fibrinogen γ’ peptide. Biophysical Chem 2007; 125: 556-559.
11 Falls LA, Farrell DH. Resistance of γA/γ’ fibrin clots to fibrinolysis. J Biol Chem 1997; 272: 14251-14256.
12 Collet JP, Nagaswami C, Farrell DH. et al. Influence of γ’ fibrinogen splice variant on fibrin physical properties and fibrinolysis rate. Arterioscler Thromb Vasc Biol 2004; 24: 382-386.
13 Cooper AV, Standeven KF, Ariëns RA. Fibrinogen γ-chain splice variant γ’ alters fibrin formation and structure. Blood 2003; 102: 535-540.
14 Gersh KC, Nagaswami C, Weisel JW. et al. The presence of γ’ chain impairs fibrin polymerization. Thromb Res 2009; 124: 356-363.
15 de Willige SU, Standeven KF, Philippou H. et al. The pleiotropic role of the fibrinogen γ’ chain in hemostasis. Blood 2009; 114: 3994-4001.
16 Drouet L, Paolucci F, Pasqualini N. et al. Plasma γA/γ’ fibrinogen ratio, a marker of arterial thrombotic activity: a new potential cardiovascular risk factor?. Blood Coagul Fibrinolysis 1999; 10: S35-39.
17 Cheung EY, Uitte de Willige S, Vos HL. et al. Fibrinogen γ’ in ischemic stroke: a case-control study. Stroke 2008; 39: 1033-1035.
18 Cheung EY, Vos HL, Kruip MJ. et al. Elevated fibrinogen γ’ ratio is associated with cardiovascular diseases and acute phase reaction but not with clinical outcome. Blood 2009; 114: 4603-4604 author reply 4604–4605.
19 Beck JD, Couper DJ, Falkner KL. et al. The Periodontitis and Vascular Events (PAVE) pilot study: adverse events. J Periodontol 2008; 79: 90-96.
20 Couper DJ, Beck JD, Falkner KL. et al. The Periodontitis and Vascular Events (PAVE) pilot study: recruitment, retention, and community care controls. J Periodontol 2008; 79: 80-89.
21 Offenbacher S, Beck JD, Moss K. et al. Results from the Periodontitis and Vascular Events (PAVE) Study: a pilot multicentered, randomized, controlled trial to study effects of periodontal therapy in a secondary prevention model of cardiovascular disease. J Periodontol 2009; 80: 190-201.
22 Ridker PM. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation 2003; 107: 363-369.
23 Beck JD, Offenbacher S. Relationships among clinical measures of periodontal disease and their associations with systemic markers. Ann Periodontol 2002; 7: 79-89.
24 Mosesson MW, Hernandez I, Raife TJ. et al. Plasma fibrinogen γ’ chain content in the thrombotic microangiopathy syndrome. J Thromb Haemost 2007; 5: 62-69.
25 Uitte de Willige S, de Visser MC, Houwing-Duistermaat JJ. et al. Genetic variation in the fibrinogen γ gene increases the risk for deep venous thrombosis by reducing plasma fibrinogen γ’ levels. Blood 2005; 106: 4176-4183.
26 Uitte de Willige S, Rietveld IM, De Visser MC. et al. Polymorphism 10034C>T is located in a region regulating polyadenylation of FGG transcripts and influences the fibrinogen γ‘/γA mRNA ratio. J Thromb Haemost 2007; 5: 1243-9.
27 de Willige SU, Pyle ME, Vos HL. et al. Fibrinogen γ gene 3’-end polymorphisms and risk of venous thromboembolism in the African-American and Caucasian population. Thromb Haemost 2009; 101: 1078-1084.